XenoPort soars off upbeat preliminary results from Phase I studies of its potential MS treatment

|By:, SA News Editor

Shares of XenoPort (XNPT +18%) soar today after the company released positive preliminary results late yesterday from two Phase I studies of XP23829.

Based on the favorable results, XNPT intends to continue to advance development of the drug as a potential treatment for patients with relapsing-remitting multiple sclerosis and/or psoriasis.